STOCK TITAN

[Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Cadrenal Therapeutics (CVKD) reported insider transactions by CEO, Chairman and Director Quang Pham, who is also a 10% owner. Under a Rule 10b5-1 trading arrangement, he sold 1,800 shares on 10/09/2025 at a weighted average price of $14.02 and 1,800 shares on 10/13/2025 at a weighted average price of $14.15. Each sale comprised multiple trades within disclosed price ranges.

Following these transactions, Mr. Pham directly beneficially owns 198,533 shares. He also indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, for which he is trustee with sole voting and disposition power.

Cadrenal Therapeutics (CVKD) ha riportato operazioni interne da parte del CEO, Presidente e Direttore Quang Pham, che è anche proprietario del 10%. Nell'ambito di un accordo di negoziazione Rule 10b5-1, ha venduto 1.800 azioni il 10/09/2025 a un prezzo medio ponderato di 14,02 dollari e 1.800 azioni il 10/13/2025 a un prezzo medio ponderato di 14,15 dollari. Ogni vendita comprendeva multiple operazioni all'interno di intervalli di prezzo divulgati.

Dopo queste operazioni, il signor Pham detiene direttamente 198.533 azioni. Detiene anche indirettamente 200.000 azioni tramite The PVBQ Living Trust, di cui è trustee con potere di voto e di disposizione esclusivo.

Cadrenal Therapeutics (CVKD) informó operaciones de insider por parte del CEO, Presidente y Director Quang Pham, quien también es propietario del 10%. Bajo un acuerdo de negociación Rule 10b5-1, vendió 1.800 acciones el 09/10/2025 a un precio medio ponderado de 14,02 dólares y 1.800 acciones el 13/10/2025 a un precio medio ponderado de 14,15 dólares. Cada venta consistió en múltiples operaciones dentro de rangos de precios divulgados.

Tras estas transacciones, el Sr. Pham posee directamente 198.533 acciones. También posee indirectamente 200.000 acciones a través de The PVBQ Living Trust, del cual es fiduciario con poder de voto y disposición exclusivo.

Cadrenal Therapeutics (CVKD)는 CEO, 의장, 이사 Quang Pham의 내부자 거래를 보고했으며, 그는 또한 10%의 소유주입니다. Rule 10b5-1 거래 약정에 따라, 그는 2025년 10월 9일에 가중 평균가 14.02달러로 1,800주를 매도했고 2025년 10월 13일에 가중 평균가 14.15달러로 1,800주를 매도했습니다. 각 매매는 공개된 가격 범위 내의 다수의 거래로 구성되었습니다.

이 거래 후 Pham 씨는 직접적으로 198,533주를 보유하고 있습니다. 또한 The PVBQ Living Trust를 통해 200,000주를 간접 보유하고 있으며, 이 신탁의 수탁자로서 단독 의결권과 처분 권한을 갖습니다.

Cadrenal Therapeutics (CVKD) a signalé des transactions d'initié du PDG, président et administrateur Quang Pham, qui est également propriétaire à hauteur de 10%. Dans le cadre d'un accord de négociation Rule 10b5-1, il a vendu 1 800 actions le 09/10/2025 à un prix moyen pondéré de 14,02 $ et 1 800 actions le 13/10/2025 à un prix moyen pondéré de 14,15 $. Chaque vente comprenait plusieurs transactions dans des fourchettes de prix divulguées.

Suite à ces transactions, M. Pham détient directement 198 533 actions. Il détient également indirectement 200 000 actions via The PVBQ Living Trust, dont il est fiduciaire avec le pouvoir de vote et de disposition exclusif.

Cadrenal Therapeutics (CVKD) meldete Insider-Transaktionen des CEO, Vorsitzenden und Direktors Quang Pham, der auch 10% Eigentümer ist. Im Rahmen einer Rule 10b5-1-Handelsregelung verkaufte er am 09.10.2025 1.800 Aktien zu einem gewichteten Durchschnittspreis von 14,02 USD und am 13.10.2025 weitere 1.800 Aktien zu 14,15 USD. Jeder Verkauf umfasste mehrere Trades innerhalb offener Preisspannen.

Nach diesen Transaktionen besitzt Herr Pham direkt 198.533 Aktien. Er besitzt zudem indirekt 200.000 Aktien über den The PVBQ Living Trust, für den er Treuhänder ist und allein Stimm- und Verfügungsgewalt hat.

Cadrenal Therapeutics (CVKD) أبلغت عن صفقات داخلية من قبل الرئيس التنفيذي والرئيس والمدير كوانغ فام، وهو أيضًا مالك بنسبة 10%. وفقًا لاتفاق تداول Rule 10b5-1، باع 1,800 سهم في 2025/10/09 بسعر متوسط مرجّح قدره 14.02 دولارًا و1,800 سهم في 2025/10/13 بسعر متوسط مرجّح قدره 14.15 دولار. كل بيع تضَمَّن عدة صفقات ضمن نطاقات أسعار مُعلَنة.

بعد هذه المعاملات، يملك السيد فام مباشرة 198,533 سهمًا. كما يملك بشكل غير مباشر 200,000 سهم عبر The PVBQ Living Trust، التي هو فيها الوصي ولديه السلطة الوحيدة في التصويت والتصرف.

Cadrenal Therapeutics (CVKD) 报告了首席执行官、董事长及董事 Quang Pham 的内幕交易,他也是10%的股东。根据 Rule 10b5-1 交易安排,他于 2025/10/09 以加权平均价 14.02 美元卖出 1,800 股,另于 2025/10/13 以加权平均价 14.15 美元卖出 1,800 股。每笔交易都是在披露的价格区间内的多笔交易。

在这些交易完成后,Pham 先生直接实际持有 198,533 股。通过 The PVBQ Living Trust 间接实际持有 200,000 股,他在该信托担任受托人,拥有单独投票和处置权。

Positive
  • None.
Negative
  • None.

Cadrenal Therapeutics (CVKD) ha riportato operazioni interne da parte del CEO, Presidente e Direttore Quang Pham, che è anche proprietario del 10%. Nell'ambito di un accordo di negoziazione Rule 10b5-1, ha venduto 1.800 azioni il 10/09/2025 a un prezzo medio ponderato di 14,02 dollari e 1.800 azioni il 10/13/2025 a un prezzo medio ponderato di 14,15 dollari. Ogni vendita comprendeva multiple operazioni all'interno di intervalli di prezzo divulgati.

Dopo queste operazioni, il signor Pham detiene direttamente 198.533 azioni. Detiene anche indirettamente 200.000 azioni tramite The PVBQ Living Trust, di cui è trustee con potere di voto e di disposizione esclusivo.

Cadrenal Therapeutics (CVKD) informó operaciones de insider por parte del CEO, Presidente y Director Quang Pham, quien también es propietario del 10%. Bajo un acuerdo de negociación Rule 10b5-1, vendió 1.800 acciones el 09/10/2025 a un precio medio ponderado de 14,02 dólares y 1.800 acciones el 13/10/2025 a un precio medio ponderado de 14,15 dólares. Cada venta consistió en múltiples operaciones dentro de rangos de precios divulgados.

Tras estas transacciones, el Sr. Pham posee directamente 198.533 acciones. También posee indirectamente 200.000 acciones a través de The PVBQ Living Trust, del cual es fiduciario con poder de voto y disposición exclusivo.

Cadrenal Therapeutics (CVKD)는 CEO, 의장, 이사 Quang Pham의 내부자 거래를 보고했으며, 그는 또한 10%의 소유주입니다. Rule 10b5-1 거래 약정에 따라, 그는 2025년 10월 9일에 가중 평균가 14.02달러로 1,800주를 매도했고 2025년 10월 13일에 가중 평균가 14.15달러로 1,800주를 매도했습니다. 각 매매는 공개된 가격 범위 내의 다수의 거래로 구성되었습니다.

이 거래 후 Pham 씨는 직접적으로 198,533주를 보유하고 있습니다. 또한 The PVBQ Living Trust를 통해 200,000주를 간접 보유하고 있으며, 이 신탁의 수탁자로서 단독 의결권과 처분 권한을 갖습니다.

Cadrenal Therapeutics (CVKD) a signalé des transactions d'initié du PDG, président et administrateur Quang Pham, qui est également propriétaire à hauteur de 10%. Dans le cadre d'un accord de négociation Rule 10b5-1, il a vendu 1 800 actions le 09/10/2025 à un prix moyen pondéré de 14,02 $ et 1 800 actions le 13/10/2025 à un prix moyen pondéré de 14,15 $. Chaque vente comprenait plusieurs transactions dans des fourchettes de prix divulguées.

Suite à ces transactions, M. Pham détient directement 198 533 actions. Il détient également indirectement 200 000 actions via The PVBQ Living Trust, dont il est fiduciaire avec le pouvoir de vote et de disposition exclusif.

Cadrenal Therapeutics (CVKD) meldete Insider-Transaktionen des CEO, Vorsitzenden und Direktors Quang Pham, der auch 10% Eigentümer ist. Im Rahmen einer Rule 10b5-1-Handelsregelung verkaufte er am 09.10.2025 1.800 Aktien zu einem gewichteten Durchschnittspreis von 14,02 USD und am 13.10.2025 weitere 1.800 Aktien zu 14,15 USD. Jeder Verkauf umfasste mehrere Trades innerhalb offener Preisspannen.

Nach diesen Transaktionen besitzt Herr Pham direkt 198.533 Aktien. Er besitzt zudem indirekt 200.000 Aktien über den The PVBQ Living Trust, für den er Treuhänder ist und allein Stimm- und Verfügungsgewalt hat.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Pham Quang X

(Last) (First) (Middle)
C/O CADRENAL THERAPEUTICS, INC.,
822 A1A NORTH, SUITE 306

(Street)
PONTE VEDRA, FL 32082

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
CEO and Chairman
3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/09/2025 S 1,800 D $14.02(1) 200,333 D
Common Stock 10/13/2025 S 1,800 D $14.15(2) 198,533 D
Common Stock 200,000 I The PVBQ Living Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.11, inclusive, having a weighted average price as shown in column 4 of $14.02. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
2. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement in multiple transactions at prices ranging from $13.99 through $14.33, inclusive, having a weighted average price as shown in column 4 of $14.15. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
3. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
/s/ Matthew K. Szot, Attorney-in-fact 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Cadrenal Therape

NASDAQ:CVKD

CVKD Rankings

CVKD Latest News

CVKD Latest SEC Filings

CVKD Stock Data

28.79M
1.51M
27.84%
7.23%
0.55%
Biotechnology
Pharmaceutical Preparations
Link
United States
PONTE VEDRA